Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to 306.28%.

  • BioCorRx's EBIT Margin changed N/A to 306.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 571.74%, marking a year-over-year increase of 175483100.0%. This contributed to the annual value of 66829.81% for FY2024, which is 625815000.0% down from last year.
  • Per BioCorRx's latest filing, its EBIT Margin stood at 306.28% for Q3 2025.
  • BioCorRx's 5-year EBIT Margin high stood at 306.28% for Q3 2025, and its period low was 33852.95% during Q2 2024.
  • Moreover, its 5-year median value for EBIT Margin was 5481.4% (2022), whereas its average is 8836.26%.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -290304400bps in 2024, then surged by 330596800bps in 2025.
  • Over the past 5 years, BioCorRx's EBIT Margin (Quarter) stood at 9790.91% in 2021, then skyrocketed by 85bps to 1430.79% in 2022, then crashed by -204bps to 4344.24% in 2023, then crashed by -679bps to 33852.95% in 2024, then skyrocketed by 99bps to 306.28% in 2025.
  • Its EBIT Margin was 306.28% in Q3 2025, compared to 793.28% in Q2 2025 and 695.29% in Q1 2025.